Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2019-01-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/268 |
| _version_ | 1797878898487197696 |
|---|---|
| author | N. A. Avxentyev A. S. Makarov M. Yu. Frolov |
| author_facet | N. A. Avxentyev A. S. Makarov M. Yu. Frolov |
| author_sort | N. A. Avxentyev |
| collection | DOAJ |
| description | Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of mCRPC patients in Russia. The aim of the current study was to develop a pharmacoeconomic tool that calculates direct medical costs (price of the drugs) of using enzalutamide or abiraterone for treatment of chemotherapy-naïve patients with mCRPC from the Russian regional healthcare systems perspective. Materials and methods. The calculator is based on a published pharmacoeconomic model of using enzalutamide or abiraterone for the 1st line treatment of mCRPC. Current regional medication prices, which explain the biggest share of direct medical treatment costs, are automatically accounted for 84 Russian regions (except nenetsky AO). The calculator also provides estimates of number of chemotherapy-naïve patients, who are eligible for enzalutamide or abiraterone treatment in each region. Results. Costs of using enzalutamide or abiraterone are almost equal on the federal level, but the differences in the costs between these two medications are higher than 10% in 15 Russian regions. Conclusions. Possible differences in costs of using enzalutamide or abiraterone should be accounted during planning of state procurements on the regional level. |
| first_indexed | 2024-04-10T02:40:23Z |
| format | Article |
| id | doaj.art-be6ae514c7f94f3fb746e80dce6950c8 |
| institution | Directory Open Access Journal |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| last_indexed | 2024-04-10T02:40:23Z |
| publishDate | 2019-01-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj.art-be6ae514c7f94f3fb746e80dce6950c82023-03-13T07:48:16ZrusIRBIS LLCФармакоэкономика2070-49092070-49332019-01-01114162710.17749/2070-4909.2018.11.4.016-027243Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancerN. A. Avxentyev0A. S. Makarov1M. Yu. Frolov2Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution; Russian Presidential Academy of National Economy and Public AdministrationInterregional Public Organization “Association of Clinical Pharmacologists”Interregional Public Organization “Association of Clinical Pharmacologists”; Volgograd State Medical University of the Ministry of Health of the Russian FederationIntroduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of mCRPC patients in Russia. The aim of the current study was to develop a pharmacoeconomic tool that calculates direct medical costs (price of the drugs) of using enzalutamide or abiraterone for treatment of chemotherapy-naïve patients with mCRPC from the Russian regional healthcare systems perspective. Materials and methods. The calculator is based on a published pharmacoeconomic model of using enzalutamide or abiraterone for the 1st line treatment of mCRPC. Current regional medication prices, which explain the biggest share of direct medical treatment costs, are automatically accounted for 84 Russian regions (except nenetsky AO). The calculator also provides estimates of number of chemotherapy-naïve patients, who are eligible for enzalutamide or abiraterone treatment in each region. Results. Costs of using enzalutamide or abiraterone are almost equal on the federal level, but the differences in the costs between these two medications are higher than 10% in 15 Russian regions. Conclusions. Possible differences in costs of using enzalutamide or abiraterone should be accounted during planning of state procurements on the regional level.https://www.pharmacoeconomics.ru/jour/article/view/268prostate cancerenzalutamideabirateronepharmacoeconomic evaluationpublic spending |
| spellingShingle | N. A. Avxentyev A. S. Makarov M. Yu. Frolov Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer Фармакоэкономика prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation public spending |
| title | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer |
| title_full | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer |
| title_fullStr | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer |
| title_full_unstemmed | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer |
| title_short | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer |
| title_sort | direct medical costs of using enzalutamide or abiraterone in chemotherapy naive patients with metastatic castration resistant prostate cancer |
| topic | prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation public spending |
| url | https://www.pharmacoeconomics.ru/jour/article/view/268 |
| work_keys_str_mv | AT naavxentyev directmedicalcostsofusingenzalutamideorabirateroneinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecancer AT asmakarov directmedicalcostsofusingenzalutamideorabirateroneinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecancer AT myufrolov directmedicalcostsofusingenzalutamideorabirateroneinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecancer |